Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment

Purpose. This study aims to asses a cancer fast-track programme (CFP) to shorten the time since a patient with suspicion of cancer is referred by the primary care (PC) physician to the specialized medical team. Methods. Guidelines for main suspected tumours were designed to help PC physicians to detect and rapidly refer cases to the CFP oncology coordinator, who sent them to the appropriate department to accelerate diagnosis, staging and therapy. All patients analysed in this report were referred from June 2009 to July 2012. Results. A total of 897 suspected cancer cases were submitted and finally 705 were studied. In 205 (29 %) a cancer diagnosis was confirmed within 23 days (median). Therapy was initiated within 46 days after referral (median). Early diagnoses with a potential curative approach were made in 166 (82 %). Conclusions. This CFP decreased the waiting time for cancer diagnosis, by improving communication between PC physician and specialized care teams. Most patients included in this program could get therapy with curative intent (AU)

No disponible

Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment.

PURPOSE: This study aims to asses a cancer fast-track programme (CFP) to shorten the time since a patient with suspicion of cancer is referred by the primary care (PC) physician to the specialized medical team. METHODS: Guidelines for main suspected tumours were designed to help PC physicians to detect and rapidly refer cases to the CFP oncology coordinator, who sent them to the appropriate department to accelerate diagnosis, staging and therapy. All patients analysed in this report were referred from June 2009 to July 2012. RESULTS: A total of 897 suspected cancer cases were submitted and finally 705 were studied. In 205 (29 %) a cancer diagnosis was confirmed within 23 days (median). Therapy was initiated within 46 days after referral (median). Early diagnoses with a potential curative approach were made in 166 (82 %). CONCLUSIONS: This CFP decreased the waiting time for cancer diagnosis, by improving communication between PC physician and specialized care teams. Most patients included in this program could get therapy with curative intent.

Mastopatía diabética: diagnóstico y tratamiento / Diabetic mastopathy: diagnosis and treatment

La mastopatía diabética abarca una serie de alteraciones estructurales de la glándula mamaria que hace años no estaban bien identificadas y que se describían, junto con otras entidades, bajo un epígrafe común: las llamadas «mastitis granulomatosas». Es una entidad infrecuente, que suele afectar a mujeres premenopáusicas con antecedente de diabetes mellitus tipo 1 de larga evolución. Se trata de una lesión histológicamente benigna, no progresiva y que no predispone a la malignización. Debe considerarse como una complicación crónica adicional de la diabetes de larga duración, al igual que lo son, por ejemplo, la nefropatía diabética o la retinopatía diabética. Conocer su existencia es importante para poder establecer el diagnóstico diferencial con el cáncer de mama. La etiología de la mastopatía diabética no está aclarada, y se invoca cierta asociación con enfermedades autoinmunitarias

Diabetic mastopathy includes a number of structural alterations of breast gland, no well identified since many years and which has been described besides other entities with the name of «granulomatous mastitis». It is an infrequent disease, which affects usually premenopausal women with type 1 diabetes of long duration. It is a benign lesion, non progressive and which will not predispose to breast cancer. The diabetic mastopathy should be considered as an additional chronic complication of diabetes of long duration as diabetic nephropathy, diabetic retinopathy, etc. The major interest remains to establish the differential diagnosis against breast cancer. The etiology of the diabetic mastopathy is not clarified enough, although an association with other autoimmune diseases has been suggested

Mastopatía diabética en una mujer con diabetes mellitus tipo 1 de larga evolución: descripción de una entidad poco conocida / Diabetic mastopathy in a woman with long-standing type 1 diabetes: a description of a poorly characterized entity

La mastopatía diabética es una forma poco frecuente de mastitis linfocitaria que aparece preferentemente en mujeres con una diabetes mellitus tipo 1 (DM1) de larga evolución. Esta entidad, con una característica proliferación fibrosa del estroma, se encuadra dentro de las lesiones mamarias fibrosas benignas, pero clínicamente puede confundirse con lesiones malignas. En este caso clínico se describe un proceso de mastopatía diabética en una paciente con DM1 de larga duración y complicaciones crónicas microvasculares conocidas, aunque controladas. Tras la detección de la lesión en una ecografía de control, fue remitida al cirujano de mama para su valoración. El diagnóstico se realizó mediante biopsia, y se descartó la presencia de lesiones malignas. El tratamiento de la mastopatía diabética fue conservador

Diabetic mastopathy is an uncommon form of lymphocytic mastitis that typically occurs in women with long-standing type 1 diabetes. This entity, which presents with a characteristic stromal fibrosis, is a benign fibrous lesion, but may clinically mimic a malignant lesion. The authors report a case involving the development of diabetic mastopathy, diagnosed in a woman with long-standing type 1 diabetes and known controlled chronic microvascular complications. After the detection of a breast lump in a routine ultrasound scan, she was referred to a breast surgeon for evaluation. The diagnosis of diabetic mastopathy was confirmed by biopsy, which ruled out the presence of malignant lesions. The management was conservative

Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor.

BACKGROUND: The aim of the study was to determine whether the number of lymph nodes removed at axillary dissection is associated with recurrence and survival in node-negative breast cancer (NNBC) patients. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 1606 women with pathologically node-negative T1-T3 invasive breast cancer. Median follow-up was 61 months (range 2-251). Potential prognostic factors assessed included: number of axillary lymph nodes examined, age, menopausal status, tumor size, histological type, tumor grade, estrogen receptor(ER), progesterone receptor (PR) and HER2. RESULTS: At 5 years, relapse-free survival (RFS) rate was 85% and breast cancer-specific survival (BCSS) rate was 94%. In univariate analysis, factors significantly associated with lower RFS and BCSS were: fewer than six lymph nodes examined (RFS, P = 0.01; BCSS, P = 0.007), tumor size >2 cm, grade III, negative ER or PR. Statistically significant factors for lower RFS and BCSS in multivariate analysis were: fewer than six lymph nodes examined [RFS, hazard ratio (HR) 1.36, P = 0.029; BCSS, HR 1.87, P = 0.005], tumor size >2 cm, tumor grade III and negative PR. CONCLUSIONS: Examination of fewer than six lymph nodes is an adverse prognostic factor in NNBC because it could lead to understaging. Six or more nodes need to be examined at axillary dissection to be confident of a node-negative status. This may be useful, in conjunction with other prognostic factors, in the assessment of NNBC patients for adjuvant systemic therapy.

Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients.

We have analyzed retrospectively 439 women with recurrent breast cancer, followed at a single institution, in order to define potential prognostic factors for survival at the time of first recurrence. Median age at the time of first recurrence was 58 and the median disease free interval (DFI) from initial diagnoses to recurrence was 33 months. Thirteen percent of the patients did not receive any adjuvant therapy while 87% received different combinations of chemotherapy, radiotherapy and hormone therapy as adjuvant treatment. With a median follow-up of 44 months from the time of recurrence the median survival (MSR) was 24 months (SE 1.24) and five-year overall survival was 18% (SE 2.02). On the univariate analysis, pathological tumor size (pT) at diagnosis (p < 0.0006), axillary lymph node status at diagnosis (p < 0.00001), negative estrogen receptor (ER) status (p < 0.0001), negative progesterone receptor (PgR) status (p < 0.0001), adjuvant chemotherapy (p < 0.001), disease free interval (p < 0.00001), location of recurrence (p < 0.0002) and number of metastatic sites (> or = 3: p < 0.0003), were significantly associated with shorter survival from first relapse. On the multivariate analysis, only the site of recurrence, axillary lymph node status at diagnosis, ER status and DFI remained independently associated with decreased MSR after first relapse.

Prognostic factors in patients with isolated recurrences of breast cancer (stage IV-NED).

BACKGROUND: One to 10% of women with metastatic breast cancer have a recurrence of their disease as an isolated lesion (local, regional, or distant) which may be treated by surgical resection, irradiation, or both. These are patients with stage IV breast cancer with no evidence of disease, or stage IV-NED. Because natural history and prognostic factors for patients with stage IV-NED are poorly determined, we decided to evaluate a group of patients with stage IV-NED treated at a single institution. PATIENTS AND METHODS: Ninety-six patients with isolated recurrence of stage IV breast cancer were analyzed retrospectively. Treatment of loco-regional or distant recurrence was surgery in 18 patients and surgery plus irradiation in 78 patients. Seventy-nine patients received systemic therapy after loco-regional treatment (24 chemotherapy and 55 hormonotherapy). Prognostic factors were analyzed and correlated with disease-free survival (DFS) and overall survival (OS). RESULTS: Five-year DFS and OS for the whole group were 29% and 49%, respectively. On the univariate analysis, patients without axillary nodal involvement at the time of mastectomy had significantly greater 5-year DFS and OS than patients with nodal involvement (51% vs. 14% and 70% vs. 34%, respectively, p < 0.05). DFS was also significantly better for patients receiving systemic therapy after local treatment (31% vs. 19%). On the multivariate analysis, absence of nodal involvement and systemic therapy were associated with longer DFS (p = 0.044 and p = 0.008, respectively) and OS (p = 0.009 and p = 0.011, respectively). None of the other factors analyzed including menopausal status, T-stage, number of involved nodes, receptor status, adjuvant therapy, sites of first recurrence, or time from mastectomy to first recurrence had a predictive value for DFS and OS. CONCLUSION: Patients with stage IV-NED have poor prognosis due to early development of metastatic disease. Absence of axillary nodal involvement at the time of mastectomy and systemic therapy following local management is associated with improved DFS and OS. These results suggest that systemic therapy after local treatment in stage IV-NED is indicated. Poor prognosis in patients with previous nodal involvement warrants new approaches.

[Surgical treatment of Zenker's diverticulum. Apropos of 14 cases]. / Tratamiento quirúrgico del divertículo de Zenker. A propósito de 14 casos.

We present our experience in the surgical treatment of 14 cases of Zenker's diverticulum, diagnosed from January, 1969 to December, 1988. In 11 cases we performed one stage diverticulectomy; in 4 cases, manometric findings required cricopharyngeal myotomy. In 3 cases surgical treatment was not indicated; 2 patients had liver cirrhosis and high surgical risk and the third patient declined the treatment. Current treatment is discussed.

Adjuvant chemotherapy with adriamycin, fluorouracil, cyclophosphamide, methotrexate, with or without tamoxifen in operable breast cancer.

Between January 1982 and February 1985, 70 breast cancer patients with histologically confirmed axillary node involvement and T1-3a were treated following surgery with a combination of adriamycin, fluorouracil, cyclophosphamide, methotrexate, with or without tamoxifen according to the estrogen and progesterone receptors state. At 60 months of study (median follow-up, 41 months), the estimated proportion remaining disease-free was 62%. The estimated survival rate was 81%. A comparison of the actuarial disease-free and overall survival with data reported in the literature indicates a similar positive effect of adjuvant systemic therapy as described in adjuvant studies using polychemotherapy regimens. Patient acception of chemotherapy regimen was generally good. This can be accounted for because of an adequate emesis control and real compliance of the patients with the oncologist.